The Alzheimer’s Drugs Market is witnessing significant growth driven by increasing prevalence of Alzheimer’s disease, a rapidly aging global population, and continuous pharmaceutical innovations. The need for effective therapies to slow, halt, or reverse the progression of Alzheimer’s has led to an influx of research, regulatory approvals, and product launches in recent years.The Alzheimer’s drugs market is witnessing steady growth as the global burden of Alzheimer’s disease continues to rise. Alzheimer's disease, a progressive neurodegenerative disorder, primarily affects memory, thinking, and behavior, eventually interfering with daily activities. As the aging population grows, so does the demand for effective treatments that can slow disease progression or manage symptoms.
According to Fortune Business Insights, the Alzheimer’s drugs market was valued at USD 3.52 billion in 2022 and is projected to grow from USD 3.69 billion in 2023 to USD 5.21 billion by 2030, exhibiting a CAGR of 5.1% during the forecast period. In 2022, North America dominated the Alzheimer’s drugs market with a market share of 51.42%.
July 2023 – The U.S. FDA granted regulatory approval for Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease. This milestone approval marks a significant breakthrough, as Leqembi offers potential to target and clear amyloid plaques, which are believed to contribute to the progression of Alzheimer’s.